ArticleClinical epigenetics2020
BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.
Article in Clinical epigenetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Subtype-Specific mInternational journal of molecular sciences · 2026Article
- Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy.Molecular therapy. Oncology · 2025Article
- Old versus new: upstream and downstream of promyelocytic leukemia zinc finger protein.Cancer gene therapy · 2025Review
- C1QL1 inhibits breast cancer through the HSP90α/VCP-ERS/UPR axis.Experimental & molecular medicine · 2025Article
- PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands.Journal of experimental & clinical cancer research : CR · 2025Article
- Identification of multiple prognostic biomarker sets for risk stratification in SKCM.Frontiers in bioinformatics · 2025Article
- Insight into the Role of the BCL6B Gene in Biological Functions and Disease Progression.Journal of Cancer · 2025Review
- Polyphyllin I exerts anti-hepatocellular carcinoma activity by targeting ZBTB16 to activate the PPARγ/RXRα signaling pathway.Chinese medicine · 2024Article
- Cancer metastases: Tailoring the targets.Heliyon · 2024Review
- ZBTB16 inhibits DNA replication and induces cell cycle arrest by targeting WDHD1 transcription in lung adenocarcinoma.Oncogene · 2024Article
- Long non-coding RNA LINC00930 targeting miR-6792-3p/ZBTB16 regulates the proliferation and EMT of pancreatic cancer.BMC cancer · 2024Article
- Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.Signal transduction and targeted therapy · 2023Article
- Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.EMBO molecular medicine · 2023Article
- BTB protein family and human breast cancer: signaling pathways and clinical progress.Journal of cancer research and clinical oncology · 2023Review
- Transcription Factor Zbtb20 as a Regulator of Malignancy and Its Practical Applications.International journal of molecular sciences · 2023Review
- Article
- spongEffects: ceRNA modules offer patient-specific insights into the miRNA regulatory landscape.Bioinformatics (Oxford, England) · 2023Article
- Article
- Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer.Genes & diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains in urgent need of reliable diagnostic and prognostic markers. Zinc finger and BTB/POZ domain-containing family proteins (ZBTBs) are important transcription factors functioning as oncogenes or tumor suppressors. The role and regulation of ZBTB16 in breast cancer remain to be established.
methodsReverse-transcription PCR and methylation-specific PCR were applied to detect expression and methylation of ZBTB16 in breast cancer cell lines and tissues. The effects of ZBTB16 in breast cancer cells were examined via cell viability, CCK8, Transwell, colony formation, and flow cytometric assays. Xenografts and immunohistochemistry analyses were conducted to determine the effects of ZBTB16 on tumorigenesis in vivo. The specific mechanisms of ZBTB16 were further investigated using Western blot, qRT-PCR, luciferase assay, and co-IP.
resultsZBTB16 was frequently downregulated in breast cancer cell lines in correlation with its promoter CpG methylation status. Restoration of ZBTB16 expression led to induction of G2/M phase arrest and apoptosis, inhibition of migration and invasion, reversal of EMT, and suppression of cell proliferation, both in vitro and in vivo. Furthermore, ectopically expressed ZBTB16 formed heterodimers with ZBTB28 or BCL6/ZBTB27 and exerted tumor suppressor effects through upregulation of ZBTB28 and antagonistic activity on BCL6.
conclusionsLow expression of ZBTB16 is associated with its promoter hypermethylation and restoration of ZBTB16 inhibits tumorigenesis. ZBTB16 functions as a tumor suppressor through upregulating ZBTB28 and antagonizing BCL6. Our findings also support the possibility of ZBTB16 being a prognostic biomarker for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.